MacroGenics (MGNX) Osake Kurssi

MacroGenics Inc is primarily active in the biotechnology industry.

The main competitors of MacroGenics Inc in the market include larger pharmaceutical companies such as Bristol-Myers Squibb, Pfizer, and Novartis. These companies also operate in the biopharmaceutical industry and have a similar focus on developing innovative therapies and treatments. MacroGenics Inc faces competition from these established players in terms of product development, market share, and financial performance. However, MacroGenics Inc has its own unique portfolio of proprietary drug candidates and strategic collaborations which help it remain competitive in the market.

MacroGenics Inc is a biopharmaceutical company based in Rockville, Maryland. Established in 2000, MacroGenics has been dedicated to developing innovative antibody-based therapies for patients with cancer and autoimmune disorders. With a strong focus on research and development, the company has built a robust pipeline of product candidates targeting different diseases. MacroGenics has achieved several milestones, including FDA approvals and collaborations with notable pharmaceutical companies. With its experienced team and cutting-edge technology, MacroGenics continues to strive towards improving patients' lives through the development of novel therapies.

MacroGenics Inc, a renowned biopharmaceutical company, has achieved several significant milestones in its impressive journey. Notably, the company successfully developed and received regulatory approvals for multiple clinical-stage product candidates, showcasing its commitment to advancing innovative therapies. MacroGenics Inc's most notable achievement includes the FDA approval of margetuximab, a treatment for patients with HER2-positive metastatic breast cancer. Moreover, the company has established strategic collaborations with leading pharmaceutical companies, further validating its research and development capabilities. With its strong focus on precision medicine and novel antibody-based therapeutics, MacroGenics Inc continues to drive breakthrough advancements in the field of biotechnology.

MacroGenics Inc is primarily present in the United States.

The values and corporate philosophy that MacroGenics Inc represents are centered around their commitment to discovering and developing innovative biopharmaceutical products. The company strives to deliver impactful medicines to improve the lives of patients. MacroGenics Inc focuses on excellence, integrity, and collaboration in their research and development efforts. They aim to be a trusted partner and create value for their stakeholders through their cutting-edge science and dedication to advancing healthcare. With a focus on science-driven discovery and a patient-centric approach, MacroGenics Inc aims to bring transformative therapies to market.

Analyytikot asettavat tällä hetkellä MacroGenics-osakkeelle keskimääräisen tavoitehinnan 6,00 USD (mediaani: 6,00 USD), mikä merkitsee +69,0 % viimeisimpään hintaan verrattuna. Konsensus perustuu 14 analyytikkoarvioon.

MacroGenics Analyytikkojen kursstavoitteet 2026

14 analyytikkoa arvioi tällä hetkellä MacroGenics-osaketta: 9 suosittaa ostoa, 5 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat MacroGenics-yhtiöltä 109,83 M USD liikevaihtoa ja −1,76 USD osakekohtaista tulosta.

MacroGenics Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla MacroGenics-osake noteerataan hintaan 3,17 EUR (3,55 USD).

MacroGenics-osake (MGNX) on listattuna 4 pörssissä, muun muassa: NASDAQ (MGNX), SIX (Zürich) (M55.SW), Frankfurt (M55.F), Düsseldorf (M55.DU).

MacroGenics Inc is a biopharmaceutical company that focuses on developing immunotherapy products for cancer and autoimmune diseases. The company aims to develop innovative therapies that can improve the lives of patients. The business model of MacroGenics comprises three main divisions: research, development, and commercialization. The company investigates the mechanisms behind the immune system to develop targeted products that can enhance immune control in diseases. To do this, the company utilizes its proprietary technology platform, the Dual-Affinity Re-Targeting (DART) technology. MacroGenics' research division focuses on the development of novel immunotherapies. An important focus is on the development of bispecific antibodies (BiTEs), which can specifically recognize and target two different antigens on tumor cells. The company already has several such products in the development phase, including MGD015, MGD017, and MGD019. MacroGenics' development division is involved in the manufacturing and testing of therapeutics and drugs that have emerged from the research division. The company has several products on the market, including the cancer immunotherapy Margetuximab (Margenza®) and Aes-103, a nasal spray for pain in cancer patients. The commercialization division of MacroGenics is responsible for the global marketing of the company's products. It also works closely with licensees and partners. One important partner of MacroGenics is Incyte Corporation, with whom the company collaborates on the development of cancer immunotherapies. MacroGenics also pursues a diversification strategy and expands into new therapy areas. The company recently entered into a partnership with Zai Lab Ltd. to jointly develop a novel antibody-drug conjugate (ADC) against HER2-positive cancer. The company has also initiated a program for the development of drugs for autoimmune diseases, including therapeutic antibodies. In addition to its commercial products, MacroGenics is also a leading provider of research services in the field of antibody and protein engineering and manufacturing. The company offers customized solutions for customers in the academic, pharmaceutical, and biotechnology sectors. Overall, MacroGenics' business model is aimed at advancing the development of innovative immunotherapy products and marketing them worldwide. With a broad product portfolio and an extensive research and development pipeline, the company is in a strong position to ensure the growth and success of the company in the future.

odotettu liikevaihto MacroGenics on 109,83 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto MacroGenics on −111,43 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

MacroGenics:n hinta-voitto-suhde (P/E) on tällä hetkellä −2,01. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan MacroGenics-osakkeen arvostusta.

MacroGenics:n hinta-myynti-suhde (P/S) on tällä hetkellä 2,04. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii MacroGenics-osakkeen arvostuskennuslukuna.

MacroGenics:n Eulpool-laatuscore on 2/10.

MacroGenics:n ISIN on US5560991094. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

MacroGenics:n WKN on A1W6ND. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

MacroGenics:n ticker on MGNX. Tämä pörssinoteeraus käytetään MacroGenics-osakkeiden kauppaan pörssissä.